Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000459

International filing date: 11 February 2005 (11.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0403041.7
Filing date: 11 February 2004 (11.02.2004)

Date of receipt at the International Bureau: 16 March 2005 (16.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

The Patent Office

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated   7 March 2005

Patents Form 1/77

ınts Act 1977
(Rule 16)

THE PATENT OFFICE
G
11 FEB 2004
LONDON

Request for grant of a patent
*(See the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help you fill in
this form)*

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1.	Your reference	AHB/CP6190722	12FEB04 E872603-1 000060 P01/7700 0.00-0403041.7 NONE

2.	Patent application number *(The Patent Office will fill this part in)*	**0403041.7** 11 FEB 2004

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

MILNER, ANNE JOSEPHINE
YCR P53 RESEARCH GROUP
DEPARTMENT OF BIOLOGY (AREA 14)
YORK
YO10 5DD

Patents ADP number *(if you know it)*

8189383002

If the applicant is a corporate body, give the
country/state of its incorporation

4. Title of the invention

INDUCTION OF APOPTOSIS

5. Name of your agent *(if you have one)*

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP

Patents ADP number *(if you know it)*

109006

6.	Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.	Country	Priority application number *(if you know it)* Date of filing *(day / month / year)*

7.	Divisionals, etc. Complete this section only if this application is a divisional application or resulted from an entitlement dispute *(see note f)*	Number of earlier UK application Date of filing *(day / month / year)*

8. Is a Patents Form 7/77 (Statement of
inventorship and of right to grant of a patent)
required in support of this request?   **YES**

Answer YES if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an
applicant, or

c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application
    must include a description of the invention.
    Not counting duplicates, please enter the number
    of pages of each item accompanying this form:

Continuation sheets of this form	0
Description	36
Claim(s)	3
Abstract	0
Drawing(s)	27 —|—27 UK

10. If you are also filing any of the following,
    state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for a preliminary examination and search (Patents Form 9/77)	0
Request for a substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	0

11. I/We request the grant of a patent on the basis of this application.

Signature(s)   *Mewburn Ellis*   Date 10 February 2004

12. Name, daytime telephone number and
    e-mail address, if any, of person to contact in
    the United Kingdom   ADRIAN H BRASNETT   020 7240 4405

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Induction of apoptosis

Field of the Invention

This invention relates to the induction of apoptosis by inhibition of SIRT1 expression, in particular the induction of

5   apoptosis in tumour cells. Materials and methods for inhibiting SIRT1 expression are provided, including RNA interference methods.

Background to the Invention

10   Many different types of stress stimulate cellular signalling pathways that result in stabilisation and activation of the tumour suppressor p53 (reviewed in Pluquet and Hainaut, 2001). Stabilisation of p53 is invariably accompanied by extensive post-translational modifications, including phosphorylation and

15   acetylation (see Appella and Anderson, 2001). Mapping the precise relationships between stress stimuli, specific modifications and the stabilisation and activation of p53 has proven extremely difficult; however general patterns and more specific correlations are now established, particularly with

20   regard to phosphorylation of the amino-terminus and acetylation of the carboxy-terminus.

The transcriptional activity of p53, with particular regard to its pro-apoptotic functions, is tightly regulated. Therefore if

25   acetylation functions to activate p53 transcriptional activity, a logical assumption would be that p53 acetylation is subject to negative control.

Until recently, deacetylation of p53 was only known to be

30   performed by members of the trichostatin A-sensitive histone

deacetylase (HDAC) class I family (Juan *et al.*, 2000; Luo *et al.*, 2000). Indeed, mounting evidence suggests that p53 utilises these HDACs to repress specific promoters (Murphy *et al.*, 1999). More recently, the human sirtuin SIRT1 (Frye, 1999)

5 has been identified as a *bona fide* p53 deacetylase (Luo *et al.*, 2001; Vaziri *et al.*, 2001).

The sirtuins are a ubiquitous gene family found throughout eukarya and prokarya, defined by conserved ~250 amino acid core

10 domain. Many of the sirtuins are NAD-dependent deacetylases ['NDAC'].

The function of *Saccharomyces cerevisiae* sirtuin SIR2 has been extensively studied. It has many activities including silencing

15 of mating-type loci, telomeric position effect silencing and silencing at the rDNA locus, suppression of illegitimate recombination and increasing cellular control of longevity. It is also implicated in response to dsDNA breaks.

20 Humans have seven sirtuins, although not all appear to have NDAC activity.

Human SIRT2 is a cytoplasmic, microtubule-associated protein. Is shows increases in abundance and phosphorylation at G2/M. It

25 is a tubulin deacetylase.and is strongly down-regulated in many gliomas and glioma cell lines. Transgene replacement causes microtubule disruption and strongly reduces the number of stable clones expressing SIRT2 compared to a control in colony formation assays)Hiratsuka, M et al (2003) Biochem Biophys Res

30 Commun. 309(3) 558-566).

Human SIRT3 is synthesized as an inactive proenzyme and activated by proteolysis on insertion into the mitochondrial matrix. Its function is unknown

5   Human SIRT1 is the closest human homologue to yeast SIR2. It is a nuclear protein found throughout the nucleus. Immunostaining of cells with anti-SIRT1 antibodies shows diffuse nuclear staining.

10   SIRT1 interacts with p53 via the p53 core and carboxy-terminus. It appears to act as a p53 deacetylase, as overexpression of SIRT1 results in reduced acetylation of p53. This in turn leads to reduced expression of endogenous p21, reduced transcription from a p21 reporter construct, and reduced apoptosis in response
15   to H_2O_2 and γ-rays.

Overexpression of a catalytically inactive mutant SIRT1 enhances acetylation of p53, and sensitises cells to apoptosis induced by H_2O_2 and γ-rays.
20
The current consensus is that SIRT1 negatively regulates p53 function via deacetylation of p53, so that inhibition of SIRT1 function sensitises cells to p53-dependent apoptosis in response to cellular stress (Luo et al., 2001; Vaziri et al., 2001;
25   Langley et al, 2002)

However, modulation of SIRT1 activity has until now been achieved by treatment of cells with the SIRT1 inhibitor nicotinamide, or by overexpression in trans of wild type and
30   catalytically inactive forms of SIRT1. The use of nicotinamide is problematic, partly due to potential inhibition of the SIRT1-related NDACs and SIRT2 and SIRT3, and partly due to potential

pleiotropic effects as nicotinamide is a natural cellular
intermediary metabolite. Recent studies have also shown that
transgene dosage may be critical in the analysis of p53 function
(Blattner *et al.*, 1999; Dumaz *et al.*, 2001), and may underlie
5   the sometimes-conflicting results that have been reported for
p53 using this technique.

Summary of the Invention

In order to elucidate the role of SIRT1 in regulating p53
10   deacetylation, p53 function and apoptosis, we sought a specific
and efficient method of inhibiting the expression or activity of
SIRT1.

We addressed the problems of the prior art methods by using a
15   more specific technique, RNA interference, to inhibit SIRT1
expression. RNA interference (RNAi) was used to analyse the
function of p53 carboxy-terminal acetylation in p53-dependent
apoptosis. The aim was to stabilise acetylation of p53 by
silencing of SIRT1. RNAi is a sequence-specific post-
20   translational gene silencing mechanism, which can be initiated
in cultured mammalian cells by transfection of a 19-21
nucleotide RNA duplex (short interfering RNA; 'siRNA')
homologous in sequence to the target mRNA (Elbashir *et al.*,
2001). Importantly, it has been demonstrated that RNAi does not
25   in itself engage the apoptotic machinery nor alter apoptotic
processes, (Jiang and Milner, 2002; Jiang and Milner 2003).

Using RNAi to inhibit SIRT1 expression, we surprisingly found
that inhibition of SIRT1 induces massive apoptosis in tumour
30   cells even without additional apoptotic stimuli. This effect is
independent of p53 and thus appears to represent a completely

new and unexpected activity of SIRT1. It also appears to be independent of the known pro-apoptotic proteins Bax and PUMA.

5   Even more surprisingly, the induction of apoptosis seen on inhibition of SIRT1 expression by RNAi appears to be specific to tumour cells, as it does not occur in normal human fibroblasts. This opens the way for new approaches to cancer treatment via the specific induction of apoptosis in tumour cells.

10   Prior to the invention, inhibition of SIRT1 expression would not have been expected to induce apoptosis in tumour cells in preference to normal cells. In fact, the opposite assumption would have been made, as it was thought that SIRT1 acted only on the p53-dependent pathway of apoptosis, and many tumour cells
15   lack functional p53. Further, it would not have been expected that inhibition of SIRT1 expression alone would induce apoptosis in the absence of other stimuli to trigger p53-dependent apoptotic pathways. The observations of the prior art indicated that inhibition of SIRT1 expression would exacerbate the
20   apoptotic phenotype of cells dying in response to agents that activate p53-dependent apoptotic pathways(Luo et al., 2001; Vaziri et al., 2001), but not that loss of SIRT1 expression itself could induce apoptosis in a p53-independent manner.

25   The invention accordingly provides for a method of inducing apoptosis in a cell comprising administering a SIRT inhibitor to the cell. Preferably, the cell is a tumour cell. In some embodiments, the cell lacks functional p53, Bax and/or PUMA protein.

30

The SIRT1 inhibitor may be an agent for inducing RNA interference in a cell, such as a siRNA, a dsRNA, or a nucleic

acid encoding such RNA. In a preferred embodiment, said agent
is a siRNA.

5 In another aspect, the invention provides a method of treating a
proliferative disease comprising administering to an individual
in need thereof an effective amount of a SIRT1 inhibitor. The
disease may be cancer, for example a colorectal carcinoma.

Thus, the invention also provides a SIRT1 inhibitor for use in a
10 method of medical treatment or therapy. The therapy may be
treatment of a proliferative disease, for example cancer. Also
provided is the use of a SIRT1 inhibitor in the manufacture of a
medicament for the treatment of a proliferative disease.

15 In another aspect, the invention provides a method of
identifying a SIRT inhibitor for use in a method of treatment of
the invention, the method comprising administering a candidate
compound to cultured tumour cells in vitro; determining whether
SIRT expression and/or activity is reduced in said cells; and
20 assaying for apoptosis of said cells. The method may further
comprise a step of administering said candidate compound to
cultured non-tumour cells in vitro and assaying for apoptosis of
said cells.

25 In another aspect, the invention provides an agent for
inhibiting the expression of SIRT1 protein in a cell. The agent
may be an agent which induces RNA interference to SIRT1 mRNA in
a cell, for example siRNA, a dsRNA, or a nucleic acid encoding
such RNA. In a preferred embodiment, the agent is a siRNA.

30

Compositions for pharmaceutical use comprising agents of the invention in combination with a pharmaceutically acceptable excipient are also provided.

5   The invention will now be described in more detail with reference to the following figures.

Brief description of the Figures

Figure 1. siRNAs used in this study.
10   SIRT1 siRNA (SEQ ID No. 1)
          Lamin A/C siRNA
          BCR-Abl siRNA

Figure 2
15   **A.**   RT-PCR showing that SIRT siRNA suppresses SIRT-1 mRNA expression.
      B.   RT-PCR of SIRT-1 in p53$^{+/+}$ cells (top) and p53$^{-/-}$ cells (bottom) transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated.
20   **C.**   Control: RT-PCR of vimentin in p53$^{+/+}$ cells (left) and p53$^{-/-}$ cells (right) transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated.
      D.   Control: RT-PCR of Lamin A/C in p53$^{+/+}$ cells (left) and p53$^{-/-}$ cells (right) transfected with SIRT1 siRNA, Lamin A/C siRNA
25   and Bcr-Abl siRNA as indicated.

Figure 3. Western blots showing that SIRT1 siRNA suppresses SIRT1 protein expression.
      A.   Western blot of whole cell lysates from cells transfected
30   with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as

indicated. Blots were probed with an anti-SIRT1 antibody and an anti-Lamin A/C antibody as shown.

B. Western blot of the soluble fraction of lysates from $p53^{+/+}$ cells (left) and $p53^{-/-}$ cells (right) transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. Equal amounts of total protein were loaded in each lane. Blots were probed with an anti-SIRT1 antibody. The bands 2' and 10' indicate 2 minute and 10 minute exposure times respectively

C. Western blot of the soluble fraction of lysates from $p53^{+/+}$ cells transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. The amount of total protein in each lane was not equalised. Blots were probed with an anti-SIRT1 antibody.

D. Western blot of the soluble fraction of lysates from $p53^{-/-}$ cells transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. The amount of total protein in each lane was not equalised. Blots were probed with an anti-SIRT1 antibody.

Figure 4 Western blots showing that SIRT1 siRNA stabilises p53 protein and increases p53 protein expression.

A. Western blot of whole cell lysates, soluble and insoluble fractions from cells transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. Blots were probed with an anti-p53 antibody.

B. Western blot of whole cell lysates (WCE), soluble (SOL) and insoluble (PEL) fractions of lysates from $p53^{+/+}$ cells (top) and $p53^{-/-}$ cells (bottom) transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. Blots were probed with an anti-p53 antibody. Recombinant human p53 was run as an antibody control.

C.   Western blot of whole cell lysates (WCE), soluble (SOL) and insoluble (PEL) fractions of lysates from p53$^{+/+}$ cells transfected with SIRT1 siRNA (top), Lamin A/C siRNA (middle) and Bcr-Abl siRNA (bottom). Blots were probed with an anti-p53 antibody. Recombinant human p53 was run as an antibody control.

Figure 5 Western blots showing that SIRT1 siRNA induces phosphorylation of p53 protein at serine 15.

A.   Western blots of whole cell lysates, soluble and insoluble fractions from cells transfected with SIRT1 siRNA. Blots were probed with the anti-p53 antibody DO-1 (top) and an anti-phosphoSer15 antibody (middle). The bottom blot was probed with antibodies to p21 and HDM2. Cells were harvested at 12, 24, 36 and 48 hours post-transfection, as indicated.

B.   Western blot of whole cell lysates (WCE), soluble (SOL) and insoluble (PEL) fractions of lysates from p53$^{+/+}$ cells transfected with SIRT1 siRNA (top right), Lamin A/C siRNA (bottom left) and Bcr-Abl siRNA (bottom right). Blots were probed with an anti-phosphoSer15 antibody. Recombinant human p53 was run as an antibody control.

C.   Western blot of whole cell lysates (WCE) from cells transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. Blots were probed with an anti-phosphoSer15 antibody.

Figure 6. Western blots showing that SIRT1 siRNA induces expression of p21.

A.   Western blot of soluble lysates from p53$^{+/+}$ cells (left) and p53$^{-/-}$ cells (right) transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. Blots were probed with an anti-p21 antibody.

B. Western blot of whole cell lysates from p53$^{+/+}$ cells incubated at 37˚C (bottom) and subjected to cold shock (top) and transfected with SIRT1 siRNA, Lamin A/C siRNA and Bcr-Abl siRNA as indicated. Blots were probed with an anti-p21 antibody.

5 SIRT1 inhibition does not induce p21 expression under conditions of cold shock.

Figure 7 Controls: Effect of SIRT siRNA on expression of Lamin A/C and Bcr-Abl.

10

Figure 8 SIRT siRNA induces apoptosis in p53$^{+/+}$ tumour cells.

A Phase contrast images of HCT116 p53$^{+/+}$ cells 24 hours and 48 hours after transfection with SIRT1 siRNA, BCR-Abl siRNA and Lamin A/C siRNA.

15 **B** Phase contrast images of HCT116 p53$^{+/+}$ cells at 12 hour timepoints after transfection with SIRT siRNA.

Figure 9 SIRT siRNA induces apoptosis in p53$^{+/+}$ tumour cells.

A Phase contrast images of HCT116 p53$^{-/-}$ cells 24 hours, 48

20 hours after transfection with SIRT1 siRNA, BCR-Abl siRNA and Lamin A/C siRNA.

Figure 10 SIRT siRNA induces apoptosis in Bax$^{-/-}$ tumour cells.

A Phase contrast images of HCT116 p53$^{+/+}$ Bax$^{-/-}$ cells 24 hours

25 and 48 hours and after transfection with SIRT1 siRNA.

Figure 11 FACS analysis showing apoptosis induced in SIRT1-transfected HCT116 p53$^{+/+}$ cells. Cells were analysed at 48 hours post-transfection.

30

Figure 12 Western blots showing Bax and PUMA expression in cells treated with SIRT1 siRNA. Blots of lysates from cells

transfected with SIRT1 siRNA were probed with an anti-Bax antibody and an anti-PUMA antibody as shown.

Figure 13 SIRT1 siRNA does not induce apoptosis in primary
human fibroblasts.
Phase contrast images of primary human normal diploid fibroblasts (NDFs) transfected with SIRT1 siRNA, taken at 2, 3, 4 and 5 days post-transfection.

Figure 14 cDNA sequence of human SIRT1 (SEQ ID No. 2).

Figure 15 Amino acid sequence alignment of human SIRT1 (SEQ ID No. 3), 2 and 3. Asterisks indicate conserved residues. ':' represents conservative amino acid substitution and '.' represents semi-conservative amino acid replacement.

Figure 16 cDNA sequence alignment of human SIRT1-7 to either side of the region of SIRT 1 covered by the SIRT-1 siRNA (shown in bold) to demonstrate specificity of SIRT1 siRNA sequences..

Figure 17 Amino acid sequence alignment of human SIRT1-7.

Detailed description

Proteins

SIRT1 refers to human sirtuin 1 as described above. SIRT1 is encoded by a nucleic acid with nucleotide sequence shown in SEQ ID No. 2 and Fig. 14. The full-length SIRT1 protein has the sequence shown in SEQ ID No. 3 and Fig. 15. The GenBank accession number for the full-length SIRT1 cDNA and amino acids sequences is NM012238.

Functional p53 protein indicates p53 protein which is capable of
inducing apoptosis. A cell lacking functional p53 protein may,
for example, carry a deletion or termination mutation of p53 so
that it does not express full length p53 at all. Alternatively,
5   the cell may express a mutant p53 which is not capable of
triggering apoptosis.

PUMA (p53 upregulated modulator of apoptosis) is a mitochondrial
protein that appears to be required for p53-mediated apoptosis
10 (Yu et al., 2003). Expression of PUMA is tightly regulated by
p53. PUMA triggers apoptosis via Bax by binding to Bcl-2 and
Bcl-X$_L$, which otherwise bind and sequester Bax.

Bax is member of the Bcl-2 family of apoptosis regulatory
15 proteins which induces apoptosis, at least in part by triggering
release of cytochrome c from mitochondria. Cytochrome c
mediates the subsequent activation of the caspases which carry
out the apoptotic death programme. Expression of Bax may also
be upregulated by p53.
20

SIRT1 inhibitor

The term 'SIRT1 inhibitor' is intended to cover any agent that
reduces the expression or activity of SIRT1 in a cell.
Alternatively, the agent may be an agent that inhibits the
25 transcription or translation of SIRT, such as an antisense DNA,
RNA or an agent that induces RNA interference.

Inhibition of SIRT expression may be detected by RT-PCR using
SIRT1-specific primers, or by Western blotting using an anti-
30 SIRT1 antibody

RNA interference

RNA interference (RNAi) is a process whereby the introduction of double stranded RNA (dsRNA) into a cell inhibits gene expression post-transcriptionally, in a sequence dependent fashion. This
5   process is also known as post-transcriptional gene silencing. Current models of RNAi indicate that it is mediated by short (typically 20-25 nucleotides) dsRNAs known as 'small interfering RNAs' (siRNA). It appears that dsRNA is cleaved in the cell to create siRNAs. siRNAs are then incorporated into an RNA-induced
10   silencing complex (RISC), guiding the complex to the homologous endogenous mRNA. The activated RISC then cleaves the mRNA transcript, resulting in the destruction of the mRNA in a cell which is homologous to the siRNAs. The siRNAs are re-cycled. In this way, a relatively small number of siRNAs can selectively
15   destroy a large excess of cellular mRNA.

To induce RNA interference in a cell, dsRNA may be introduced into the cell as an isolated nucleic acid fragment or via a transgene, plasmid or virus. Alternatively, siRNA may be
20   synthesised and introduced directly into the cell.

siRNA sequences are selected on the basis of their homology to the gene it is desired to silence. Homology between two nucleotide sequences may be determined using a variety of
25   programs including the BLAST program, of Altschul et al. (1990) *J. Mol. Biol.* 215: 403-10, or BestFit, which is part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711). Sequence comparisons may be made using FASTA and FASTP
30   (see Pearson & Lipman, 1988. Methods in Enzymology 183: 63-98). Parameters are preferably set, using the default matrix, as

follows: Gapopen (penalty for the first residue in a gap): -16 for nucleic acid; Gapext (penalty for additional residues in a gap): -4 for nucleic acids; KTUP word length: 6 for nucleic acids.

Sequence comparison may be made over the full length of the relevant sequence, or may more preferably be over a contiguous sequence of about or 10, 15, 20, 25 or 30 bases.

Preferably the degree of homology between the siRNA and the target gene is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99%.

The degree of homology between the siRNA or dsRNA and the gene to be silenced will preferably be sufficient that the siRNA or dsRNA will hybridise to the nucleic acid of the gene sequence under stringent hybridisation conditions.

Typical hybridisation conditions use 4-6 x SSPE; 5-10x Denhardts solution, 5g polyvinylpyrrolidone and 5g bovine serum albumin; 100µg-1mg/ml sonicated salmon sperm DNA; 0.1-1% sodium dodecyl sulphate; optionally 40-60% deionised formamide. Hybridisation temperature will vary depending on the GC content of the nucleic acid target sequence but will typically be between 42°C-65°C. Sambrook et al (2001) Molecular Cloning: A Laboratory Approach (3rd Edn, Cold Spring Harbor Laboratory Press). A common formula for calculating the stringency conditions required to achieve hybridisation between nucleic acid molecules of a specified homology is:

$$T_m = 81.5°C + 16.6\text{Log}[Na^+] + 0.41[\%G+C] - 0.63(\% \text{ formamide}).$$

The siRNA may be between 10bp and 30bp in length, preferably

between 20bp and 25bp. Preferably, the siRNA is 19, 20, 21 or 22bp in length.

5   The siRNA sequence may be, for example, any suitable contiguous sequence of 10-30bp from the sequence shown in Fig 14 (SEQ ID No. 2). Alternatively, longer dsRNA fragments comprising contiguous sequences from the sequences of Fig 14 (SEQ ID No. 2) may be used, as they will be cleaved to form siRNAs within the cell. Preferably, the siRNA sequence is that shown in Fig 1a

10 (SEQ ID No. 1).

In a preferred embodiment, the siRNA has the 19bp sequence shown in Fig 1. In some embodiments, the siRNA has an overhang at one or both ends of one or more deoxythymidine bases. The overhang

15 is not to be interpreted as part of the siRNA sequence. Where present, it serves to increase the stability of the siRNA within cells by reducing its susceptibility to degradation by nucleases.

20 siRNA molecules may be synthesized using standard solid or solution phase synthesis techniques which are known in the art. Linkages between nucleotides may be phosphodiester bonds or alternatives, for example, linking groups of the formula $P(O)S$, (thioate); $P(S)S$, (dithioate); $P(O)NR'2$; $P(O)R'$; $P(O)OR6$; CO; or

25 $CONR'2$ wherein R is H (or a salt) or alkyl (1-12C) and R6 is alkyl (1-9C) is joined to adjacent nucleotides through-O-or-S-.

Alternatively, siRNA molecules or longer dsRNA molecules may be made recombinantly by transcription of a nucleic acid sequence,

30 preferably contained within a vector as described below.

Modified nucleotide bases can be used in addition to the

naturally occurring bases, and may confer advantageous
properties on siRNA molecules containing them.

For example, modified bases may increase the stability of the
5   siRNA molecule, thereby reducing the amount required for
silencing. The provision of modified bases may also provide
siRNA molecules which are more, or less, stable than unmodified
siRNA.

10   The term 'modified nucleotide base' encompasses nucleotides with
a covalently modified base and/or sugar. For example, modified
nucleotides include nucleotides having sugars which are
covalently attached to low molecular weight organic groups other
than a hydroxyl group at the 3'position and other than a
15   phosphate group at the 5'position. Thus modified nucleotides may
also include 2'substituted sugars such as 2'-O-methyl- ; 2-O-
alkyl ; 2-O-allyl ; 2'-S-alkyl; 2'-S-allyl; 2'-fluoro- ; 2'-halo
or 2; azido-ribose, carbocyclic sugar analogues a-anomeric
sugars; epimeric sugars such as arabinose, xyloses or lyxoses,
20   pyranose sugars, furanose sugars, and sedoheptulose.

Modified nucleotides are known in the art and include alkylated
purines and pyrimidines, acylated purines and pyrimidines, and
other heterocycles. These classes of pyrimidines and purines are
25   known in the art and include pseudoisocytosine, N4,N4-
ethanocytosine, 8-hydroxy-N6-methyladenine, 4-acetylcytosine,5-
(carboxyhydroxylmethyl) uracil, 5 fluorouracil, 5-bromouracil,
5-carboxymethylaminomethyl-2-thiouracil, 5-
carboxymethylaminomethyl uracil, dihydrouracil, inosine, N6-
30   isopentyl-adenine, 1- methyladenine, 1-methylpseudouracil, 1-
methylguanine, 2,2-dimethylguanine, 2methyladenine, 2-
methylguanine, 3-methylcytosine, 5-methylcytosine, N6-

methyladenine, 7-methylguanine, 5-methylaminomethyl uracil, 5-
methoxy amino methyl-2-thiouracil, -D-mannosylqueosine, 5-
methoxycarbonylmethyluracil, 5methoxyuracil, 2 methylthio-N6-
isopentenyladenine, uracil-5-oxyacetic acid methyl ester,
5   psueouracil, 2-thiocytosine, 5-methyl-2 thiouracil, 2-
thiouracil, 4-thiouracil, 5methyluracil, N-uracil-5-oxyacetic
acid methylester, uracil 5-oxyacetic acid, queosine, 2-
thiocytosine, 5-propyluracil, 5-propylcytosine, 5-ethyluracil,
5ethylcytosine, 5-butyluracil, 5-pentyluracil, 5-pentylcytosine,
10   and 2,6,diaminopurine, methylpsuedouracil, 1-methylguanine, 1-
methylcytosine.

Vectors

The invention also provides vectors comprising a nucleotide
15   sequence encoding an siRNA or longer RNA or DNA sequence for
production of dsRNA. The vector may be any RNA or DNA vector.
The vector is preferably an expression vector, wherein the
nucleotide sequence is operably linked to a promoter compatible
with the cell. The vector will preferably have at least two
20   promoters, one to direct expression of the sense strand and one
to direct expression of the antisense strand of the dsRNA.
Alternatively, two vectors may be used, one for the sense strand
and one for the antisense strand. Alternatively the vector may
encode RNAs which form stem-loop structures which are
25   subsequently cleaved by the cell to produce dsRNA.

Where the vector is an expression vector, the sequence to be
expressed will preferably be operably linked to a promoter
functional in the target cells. Promoters suitable for use in
30   various vertebrate systems are well known. For example,
suitable promoters include viral promoters such as mammalian

retrovirus or DNA virus promoters, e.g. MLV, CMV, RSV, SV40 IEP and adenovirus promoters and metallothionein promoter. The CMV IEP may be more preferable for human use. Strong mammalian promoters may also be suitable as well as RNA polymerase II and

5   III promoters. Variants of such promoters retaining substantially similar transcriptional activities may also be used.

Other vehicles suitable for use in delivering nucleic acids such

10 as siRNAs include viruses and virus-like particles (VLPs) such as HPV VLPs comprising the L1 and/or L2 HPV viral protein; or hepatitis B viral proteins. Other suitable VLPs may be derived from picornaviruses; togaviruses; rhabdoviruses; orthomyxoviruses; retroviruses; hepadnaviruses; papovaviruses;

15 adenoviruses; herpesviruses; and pox viruses.

Delivery

Various agents may be used to improve the delivery of RNA, DNA or protein into the cell. Viral vectors as described above may

20 be used to deliver nucleic acid into a cell. Where other vectors, or no vector, is used, delivery agents such as liposomes may usefully be employed. Delivery peptides such as Antennapedia of the HIV TAT peptide may be used, as may organic polymers such as a dendrimers or polylysine-transferrine-

25 conjugates.

Liposomes can be prepared from a variety of cationic lipids, including DOTAP, DOTMA, DDAB, L-PE, and the like. Lipid carrier mixtures containing a cationic lipid, such as N-[1-(2,3-

30 dioleyloxy) propyl]-N,N,N-triethylammonium chloride (DOTMA) also known as "lipofectin", dimethyl dioctadecyl ammonium bromide

(DDAB), 1,2-dioleoyloxy-3-(trimethylammonio) propane (DOTAP) or L-lysinyl-phosphatidylethanolamine (L-PE) and a second lipid, such as dioleoylphosphatidylethanolamine (DOPE) or cholesterol (Chol), are particularly useful for use with nucleic acids.

5   DOTMA synthesis is described in Felgner, et al., (1987) Proc. Nat. Acad. Sciences, (USA) 84:7413-7417. DOTAP synthesis is described in Stamatatos, et al., Biochemistry, (1988) 27:3917-3925.

10   Liposomes are commercially available from many sources. DOTMA:DOPE lipid carriers can be purchased from, for example, BRL.   DOTAP:DOPE lipid carriers can be purchased from Boehringer Mannheim.   Cholesterol and DDAB are commercially available from Sigma Corporation.   DOPE is commercially available from Avanti

15   Polar Lipids.   DDAB:DOPE can be purchased from Promega. Invitrogen make liposomes under the names oligofectamine™ and lipofectamine™.

To incorporate nucleic acid into liposomes, the liposome-nucleic

20   acid complex is prepared by mixing with the nucleic acid in an appropriate nucleic acid:lipid ratio (for example 5:3) in a physiologically acceptable diluent (for example Opti-MEM™ at an appropriate dilution) immediately prior to use.

25   *Apoptosis assays*

The induction of apoptosis in cells may be assayed by many methods.

Apoptotic cells in culture may be detected and assayed by

30   photomicrography; apoptotic cells may be detected by their distinctive morphology, with blebbing of the plasma membrane and

chromatin condensation and fragmentation. DNA dyes such as propidium iodide (PI) or Hoechst 33342 may be used to detect chromatin condensation. Alternatively, TUNEL may be used to detect DNA strand breaks.

Antibodies such as anti-annexin V can be used to label apoptotic cells and detected by immunofluorescence, and assayed by micrography of FACS analysis.

FACS analysis may be used in combination with a DNA dye such as PI, TUNEL and/or annexin staining. Apoptotic cells may be detected as a sub-G1 fraction of cells which have lost DNA.

Release of cytochrome c from mitochondria is another marker for apoptosis. A measure of the early stages of apoptosis may be obtained by fractionating cell lysates into mitochondrial and cytoplasmic fractions and detecting the amount of cytochrome c released from the mitochondria into the cytosol. This is usually done by performing a Western blot and probing with an anti-cytochrome c antibody.

Proliferative disease

A proliferative disease is a pathological condition characterised by unwanted cell growth. In general, proliferative diseases can be divided into two types: clonal and non-clonal. Clonal proliferative disease usually leads to the formation of tumours, which may be benign or malignant (cancerous). Cancers may be cancer of the skin, connective tissue, adipose, breast, lung, stomach, pancreas, ovary, cervix, uterus, kidney, bladder, colon, prostate, central nervous system (CNS), retina and circulating tumours (such as leukaemia and

lymphoma). Colorectal cancer includes cancers of the colon, rectum, anus, and appendix.

SIRT inhibitors may be effective in providing treatments that
5   discriminate between malignant and normal cells, avoiding many of the deleterious side-effects present with most current chemotherapeutic regimes.

Non-clonal proliferative diseases include psoriasis, fibrocystic
10   disease, myelofibrosis, proliferative diabetic retinopathy, atherosclerosis (associated with proliferation of vascular cells) and chronic inflammatory proliferative diseases (CIPD).

As used herein, 'tumour cells' shall be taken to refer both to
15   cells derived from tumours, including malignant tumours, and cells immortalised in vitro. 'Normal' cells refers to cells with normal growth characteristics that do not show abnormal proliferation.

20   'Therapy' and 'treatment' of disease includes any therapy or treatment that alleviates in any way the symptoms of a disease. These terms refer to any administration of the compound, salt or N-oxide thereof, intended to alleviate the severity of a disorder of the GI tract in a subject, and includes treatment
25   intended to cure the disease, provide relief from the symptoms of the disease and to prevent or arrest the development of the disease in an individual at risk from developing the disease or an individual having symptoms indicating the development of the disease in that individual.
30

Compositions

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may include, in addition to active ingredient, a pharmaceutically

5   acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of

10   administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.

For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol,

15   lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, acetylated triglycerides and the

20   like, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and

25   the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate,

30   triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such

dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins. The composition or formulation to be administered will, in any

5   event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

Administration

10   Where a composition as described herein is to be administered to an individual, administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to

15   the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. It will also depend upon toxicity of the therapeutic agent, as determined by pre-clinical and clinical trials.

20

Dosing is dependent on severity and responsiveness of the condition to be treated, with course of treatment lasting from several days to several months or until a diminution of disease state is achieved. Optimal dosing schedules are easily

25   calculated from measurements of drug accumulation in the body. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Therapeutically or prophylactically effective amounts (dosages) may vary depending on the relative potency of individual compositions, and can

30   generally be routinely calculated based on molecular weight and EC50s in in vitro and/or animal studies. For example, given the molecular weight of an siRNA drug compound (derived from

oligonucleotide sequence and chemical structure) and an
experimentally derived effective dose such as an IC_{50}, for
example, a dose in mg/kg is routinely calculated. In general,
dosage is from 0.001µg to 100g and may be administered once or
5   several times daily, weekly, monthly or yearly.

Compositions of the present invention may be administered in a
number of ways depending upon whether local or systemic
treatment is desired and upon the area to be treated.
10   Administration may be topical (including ophthalmic, vaginal,
rectal, intranasal, epidermal and transdermal), oral or
parenteral. Parenteral administration includes intravenous
drip, subcutaneous, intraperitoneal or intramuscular injection,
pulmonary administration, e.g., by inhalation or insufflation,
15   or intracranial, e.g., intrathecal or intraventricular,
administration.

Prescription of treatment, e.g. decisions on dosage etc, is
within the responsibility of general practitioners and other
20   medical doctors. A composition may be administered alone or in
combination with other treatments, either simultaneously or
sequentially dependent upon the condition to be treated.

The invention is illustrated by the following examples.
25

Experimental procedures

Design of siRNA specific to SIRT1
A siRNA sequence located adjacent to the conserved sirtuin
30   domain on the carboxy-terminal side was selected on the basis of
its selectivity for SIRT1 and its predicted lack of secondary
structure.

Bestfit matching to other sirtuin cDNAs was performed and the results were: SIRT2/3/7 – 57.9%
SIRT4/5/6 – 63.2%

BLAST searching of GenBank, EMBL, DDBJ and PDB databases was performed and the results were:
Matches 1-8 :Human SIRT1 [some truncated clones].
Match 9: *Streptococcus mutans* sequence [imperfect].
Match 10: *Mus musculus* sequence [imperfect].

BLAST searching of the Genbank Human EST database was performed and the results were:
Matches 1-4: Human SIRT1.
Matches 5-10: Misc. sequences [imperfect].

These results showed that the selected sequence was likely to be specific for SIRT RNA.

The biophysical properties and predicted secondary structure formation of the selected sequence was
Tm: 46°C
GC: 42.1%
Loop: No
Secondary structure: No

Taken together, these results indicated that the selected sequence was likely to be effective in inducing RNA interference specific for the SIRT1 mRNA.

Control siRNAs were Lamin A/C siRNA (purchased from Dharmacon) and Bcr-Abl siRNA (siACE RNA, obtained from Dr Ming Jiang). A

further control, indicated in the figures as CTRL or Mock, was the transfection of siRNA buffer alone (no siRNA).

RT-PCR

5 RT-PCR for SIRT1, Lamin A/C, BCR-Abl and controls (vimentin and GAPDH) was performed.

A SIRT1 upstream [5'] primer located in conserved core domain, over an exon-exon boundary, and a downstream [3'] primer located in SIRT1-specific sequence were selected.

10 RT-PCR was performed from total RNA using a Reverse-It One-Step kit (ABgene) according to the manufacturer's instructions, and visualised on 2% TAE gels with ethidium bromide.

Primers were as follows:

SIRT1 sense 5-TCAGTGTCATGGTTCCTTTGC-3; SIRT1 antisense 5-

15 AATCTGCTCCTTTG

CCACTCT;

Lamin A sense 5-AAGCAGCGTGAGTTTGAGAGC-3;

Lamin A antisense 5-AGGGTGAACTTTGGTGGGAAC-3;

GAPDH sense 5-CGGAGTCAACGGATTTG

20 GTCGTAT-3;

GAPDH antisense 5-AGCCTTCTCCATGGTGGTGAAGAC-3.

Vimentin sense: 5-gCCAACTACATCgACAAggTg-3

Vimentin antisense: 5-gAgCAggTCTTggTATTCACg-3

25

Western blotting

Cells for protein lysates were washed in PBS and lysed in buffer IPAX (10 mM TRIS base pH 8.0, 140 mM NaCl, 0.5% NP40, 1 mM PMSF, 1x Complete Protease Inhibitors (Roche), 50 mM NaF, 1 mM Na_3VO4,

30 1 µM trichostatin A, 10 mM nicotinamide). Lysates were spun at 13 000g for 20 minutes at 4°C to separate soluble and insoluble fractions, where indicated. Mitochondrial and cytosolic

fractions were prepared as previously described (Marsden *et al.*, 2002), where indicated. Lysates were run on 10% or 15% SDS-PAGE, electroblotted to Protran membrane (Schleicher & Schuell), and probed with antibodies as described below. Visualisation
5   was with the POD chemiluminescence kit (Roche).

Blots were probed with the following antibodies:
anti-SIRT1 (H-300, Santa Cruz); anti-p53 (DO-1, Oncogene); anti-phosphoserine 15 (Ser15-R, Santa Cruz), anti-p21 (SX118,
10   Pharmingen); anti-HDM2 (monoclonal antibody 4B2, prepared in-house); anti-lamin A/C (636, Santa Cruz); Anti-Abl(8E9, Pharmingen); anti-Bax (N-20, Santa Cruz); anti-PUMAα (AHP727, Serotec) and anti-cytochrome c (7H8.2C12, Pharmingen).

15   **Photomicrography**
Phase contrast images were captured with an Axiovert 200M Cell Observer platform (Zeiss) at various time points post-transfection.

20   **Cell cycle analysis**
Cells were fixed with 70% ethanol at -20°C, washed with PBS and incubated for 15 minutes at room temperature in PBS containing $10U$ ml^{-1} RNaseA and 30μ ml^{-1} propidium iodide. Samples were analysed on a FACSCalibur flow cytometer (Beckton Dickinson)
25   using CellQuest software.

Results

Example 1
Inhibition of SIRT expression by RNAi
30   A siRNA specific to human SIRT1 was designed which had no more than ~60% homology to any other human sirtuin cDNA (Figure 1A).

BLAST searching of human genomic and EST databases reported only the SIRT1 gene itself as a significant match. As a positive control we used an siRNA directed to lamin A/C (Dharmacon; Elbashir *et al*., 2001) (Fig 1B); as a negative control we used

5   an siRNA directed to the BCR-ABL fusion oncogene (MWG-Biotech) which is biologically active only in a background of BCR-ABL (Fig 1C). The siRNAs were introduced to wild-type or $p53^{-/-}$ or Bax^{-1-} HCT116 colorectal cancer cells by cationic-based lipid transfection (Oligofectamine™, Invitrogen) according to the

10   manufacturer's instructions. Cells were harvested 48 hours post-transfection for the preparation of total cellular RNA and at 12 hour intervals post-transfection for the preparation of protein lysates and protein lysates.

15   One-step RT-PCR showed that only the SIRT1 siRNA reduced the abundance of SIRT1 mRNA (Fig 2B); the mock transfections and control siRNAs did not alter SIRT1 mRNA. RT-PCR specific for the lamin A mRNA demonstrated that the lamin A/C siRNA was active in HCT116 cells (Fig 2D), and therefore that an active

20   siRNA process does not alter SIRT1 mRNA.

Additionally, silencing of SIRT1 mRNA did not alter lamin A mRNA, and none of the siRNAs altered abundance of the mRNAs chosen as controls, vimentin (Fig 2C) and GAPDH (Fig2A). These

25   data support the specificity of the SIRT1 siRNA for RNAi.

Western blots were performed to establish the efficacy of RNAi in inhibiting protein expression. Figs 3A and 7A/B show that only LaminA/C siRNAs silence Lamin A protein expression in $p53^{+/+}$

30   cells (top) and $p53^{-/-}$ cells under optimal growth conditions, but silencing of SIRT1 can downregulate LaminA if cellular stress is applied. (Note that the antibody used does not seem to recognise

Lamin A in whole cell lysates). Fig 7C/D confirms that BCR-Abl siRNA does not induce RNAi in cells lacking BCR-ABL. Fig 3 demonstrates the efficacy of SIRT1 siRNA in reducing SIRt1 protein expression.

5

Significant silencing at the protein level was observed for LaminA/C which had not been indicated by the RT-PCR. This suggests that the relationship between silencing at the mRNA and protein levels is not linear. Likewise, blots probed for SIRT1

10 showed a profound silencing at the protein level (Figure 3) although RT-PCR had shown only ~50% mRNA degradation. Possibly this reflects protection or sequestration of a pool of the mRNA, such that it is not accessible to components of the RNAi machinery.

15

Example 2

Effect of SIRT1 siRNA on p53 stability and activity

We went on the investigate the effect of SIRT1 siRNA on p53 stability and activity. In response to cellular stress, it

20 appears that stabilisation of p53 requires only its prior destabilisation by HDM2 (Blattner et al., 1999). The most significant post-translational modification in this regard is phosphorylation of serine 20, now generally accepted as the major mechanism through which p53 is removed from HDM2-mediated

25 negative regulation (Chehab et al., 1999; Dumaz et al., 2001). Phosphorylation of serine 15, previously thought to be involved in stabilisation of p53 (Shieh et al., 1997; Unger et al., 1999), is now believed to be primarily involved in the activation of p53 as a transcription factor (Dumaz and Meek,

30 1999). The acetylation of the carboxy-terminus of p53 occurs in response to most stimuli that stabilise p53 (Itoh et al., 2001).

Although the function of acetylation of p53 is not fully understood it appears to be stimulated by phosphorylation of serine 15 (Dumaz and Meek, 1999; Lambert et al., 1998), implicated in nucleotide excision repair (Rubbi and Milner, 2003) and in the recruitment of acetylase enzymes to chromatin (Espinosa and Emerson, 2001), and required for efficient p53-dependent apoptosis (Luo et al., 2001; Vaziri et al., 2001). Although it has been demonstrated that, under certain circumstances, neither amino-terminal phosphorylation nor carboxy-terminal acetylation are obligate events for the stabilisation and activation of p53 (Blattner et al., 1999; Ashcroft et al., 2000), the weight of evidence supports a general model whereby stress stimuli signal to p53 via phosphorylation of amino-terminal serine residues. These phosphorylations stabilise p53 and promote interaction with acetylase enzymes; acetylation of the carboxy-terminus fully activates p53 as a transcription factor and may help stabilise p53 (Nakamura et al., 2000).

To determine if silencing of SIRT1 could stabilise p53, we performed Western blots using the pantropic anti-p53 antibody DO-1 in cells treated with SIRT1. This revealed that silencing of SIRT1 led to a significant stabilisation of p53 (Fig 4) compared to the mock transfected control. It is possible that the RNAi process itself constitutes a low-level stress signal, as a small stabilisation of p53 was observed for the lamin A/C siRNA but not the BCR-ABL siRNA. Interestingly, the p53 stabilised by the SIRT1 siRNA was partitioned between the soluble (cytoplasmic and nucleoplasmic) fraction and the insoluble fraction protein, thought the p53 stabilised by LaminA/C silencing was found only in the soluble fraction.

We then examined in more detail the stabilisation and activation of p53 in HCT116 cells transfected with SIRT1 siRNA. We chose to examine a four-point time course, with sampling at 12, 24, 36 and 48 hours post-transfection. Protein lysates and fractions were prepared and blotted with antibodies to p53 and phosphoSer15 (Figs 4 and 5).

Significant stabilisation of p53 was not observed in whole cell lysates until 36 hours post-transfection, although the soluble fraction showed that there was stabilisation at 24 hours (Fig 4). Intriguingly, stabilised p53 was not detected in the insoluble fraction until 36 hours post-transfection, and was not highly elevated until 48 hours.

To analyse the activation of p53 as a transcription factor we examined phosphorylation of serine 15. We determined that stabilised p53 was not subject to serine 15 phosphorylation prior to 36 hours post-transfection. Furthermore, that serine 15 phosphorylation was restricted to p53 in the soluble fraction, as no phosphorylation of this residue was detected at any time point in the insoluble fraction (Fig 5). LaminA/C silencing can induce a very small amount of phosphorylation, and BCR-ABL siRNAs do not stimulate phosphorylation.

This data is somewhat counter-intuitive, as one might assume that transcriptionally competent p53 would be associated with chromatin. However, these cells were cultured under normal conditions and in the absence of any exogenous stress stimulus. It was therefore possible that although the p53 was stabilised and "activated", additional signals or cofactors not present or accessible to the p53 under these conditions were required to activate gene transcription.

Example 3

Effect of SIRT1 siRNA on downstream activity of p53

To investigate this, we analysed expression of the two best-
characterised p53 responsive genes, p21(CIP1/WAF1) and HDM2.
The results for these were essentially identical, as both showed
a strong induction of expression at 36 hours that was absent
prior to this time point (Figs 5A and 6). There was therefore a
good temporal correlation in this data between stabilisation of
p53, "activating" post-translational modification, and the
induction of transcriptional targets. This effect was seen only
in p53$^{+/+}$ cells, indicating that the p21 expression was indeed
induced by p53 (Fig 6A). Silencing of SIRT1 does not induce
expression of p21 if cellular stress is applied (Fig 7B).

Example 4

SIRT1 siRNA induces apoptosis in tumour cells independently of
p53

As p21 was effectively induced, we wondered if these cells were
cell cycle arrested. Phase contrast images (Figs 8 and 9) showed
a very clear phenotype that was apparent at 36 hours, and
pronounced by 48 hours. Close examination of these cells under
higher magnification revealed reduction of the cell bodies,
extensive membrane blebbing and a granular appearance to the
nucleus (Fig 8C). Surprisingly, this effect was seen in p53$^{-/-}$
cells (Fig 9) as well as p53$^{+/+}$ cells (Fig 8), indicating that
the apoptosis observed was not occurring via a p53-dependent
pathway, counter to previous findings.

As these morphological changes are typical of apoptosis, we
analysed control and SIRT1-silenced HCT116 cells by flow
cytometry (Figure 11). Propidium iodide staining revealed that

there was no significant change in the cell cycle profile of cells transfected with either the lamin A/C or BCR-ABL siRNAs, as compared to the mock-transfected controls. Cells treated with the SIRT1 siRNA showed a marked decrease of the G1 and G2/M

5   populations and a significant increase in sub-G1 population, consistent with apoptotic chromatin fragmentation.

As cells treated with SIRT1 siRNA were clearly undergoing apoptosis, we next considered whether in p53$^{+/+}$ cells the

10 stabilised p53 induced the expression of components of the pro-apoptotic machinery. Activation of p53 in HCT116 cells has previously been demonstrated to induce expression of two pro-apoptotic genes, PUMA and Bax (Yu *et al.*, 2003; Zhang *et al.*, 2000). Neither Bax nor PUMA was induced in SIRT1-silenced

15 cells, as compared to the controls (Fig 12A). Indeed, PUMA appeared to be repressed by transfection of the cells with SIRT1 siRNA. Further, SIRT siRNA induced apoptosis even in p53$^{+/+}$ cells lacking Bax (Fig 10). These results indicate that SIR1 siRNA can induce apoptosis via a p53-independent mechanism even

20 in p53$^{+/+}$ cells

Two modes of apoptosis are present in human cells: The intrinsic pathway, which functions through mitochondria, and the extrinsic pathway, which functions through the activation of cell death

25 receptors (for review see Green, 1998). PUMA and Bax are both components of the intrinsic pathway, and as neither was induced by the stabilised p53, it was necessary to determine which apoptotic pathway had been activated.

30 The discovery of cross-talk between the intrinsic and extrinsic pathways (Green, 1998) has been complicated by the discovery that cell type determines the extent of cross-talk. This has led

to the idea that cells fall into one of two types. Type I cells can undergo death receptor induced apoptosis independently of mitochondria; type II cells require mitochondrial involvement for death receptor signalling to induce apoptosis (Scaffidi *et al.*, 1998). Importantly, it has been established that HCT116 cells exhibit the behaviour of type II cells (Deng *et al.*, 2002), which implies that the apoptosis induced by SIRT1 treatment most likely functions through mitochondria.

Example 5

SIRT1 siRNA does not induce apoptosis in normal cells

We decided to test the effect of SIRT1 siRNA on a non-tumour cell line. Treatment of primary human normal diploid fibroblasts (NDFs) with SIRT1 siRNA not only failed to provoke the massive apoptosis seen in HCT116 cells, it did not appear to induce apoptosis at all. Cells were still healthy 5 days post-transfection (Fig 13).

We have demonstrated that silencing of SIRT1 in HCT116 colorectal cancer cells provokes massive apoptosis. The tumour suppressor p53 is stabilised in response to SIRT1 silencing, and undergoes at least partial activation for transcriptional function. This effect is independent of p53, and we did not detect induction of either PUMA or Bax, two pro-apoptotic genes that have been shown to be critical for p53-dependent apoptosis in colorectal cancer cells. Moreover, apoptosis was not induced by SIRT1 siRNA in normal cells, indicating this effect may be specific to tumour cells.

References

Appella E and Anderson C W. (2001). Eur. J. Biochem., 268, 2764-2772.

Ashcroft M, Taya Y and Vousden K H. (2000). Mol. Cell. Biol., 20, 3224-3233.

Blattner C, Tobiasch E, Liffen M, Rahmsdorf H J and Herrlich P. (1999). Oncogene, 18, 1723-1732.

Chehab N H, Malikzay A, Stavridi E S and Halazonetis T D. (1999). Proc. Natl. Acad. Sci. USA, 96, 13777-13782.

Dumaz N and Meek D W. (1999). Embo J., 18, 7002-7010.

Dumaz N, Milne D M, Jardine L J and Meek D W. (2001). Biochem. J., 359, 459-464.

Elbashir S M, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T. (2001). Nature, 411, 494-498.

Espinosa J M and Emerson B M. (2001). Mol. Cell, 8, 57-69.

Frye R. (1999). Biochem. Biophys. Res. Commun., 273, 793-798.

Green D R. (1998). Cell, 94, 695-698.

Ito A, Lai C-H, Zhao X, Saito S, Hamilton M H, Appella E and Yao, T-P. (2001). EMBO J., 20, 1331-1340.

Jiang M and Minler J. (2002). Oncogene, 21, 6041-6048.

Jiang M and Milner J. (2003). Genes Dev., 17, 832-837.

Juan L-J, Shia W J, Chen M H, Yang, W M, Seto E, Lin Y S and Wu C W. (2000). J. Biol. Chem., 275, 20436-20443.

Lambert P F, Kashanchi F, Radonovich M F, Shiekhattar R and Brady J N. (1998). J. Biol. Chem., 273, 33048-33053.

Langley, E. et al., (2002) EMBO J 21/2383-2396.

Luo J, Nikolaev A Y, Imai S, Chen D, Su F, Shiloh A, Guarente L and Gu W. (2001). Cell, 107, 137-148.

Luo J, Su F, Chen D, Shiloh A and Gu W. (2000). Nature, 408, 377-381.

Marsden V S, O'Connor L, O'Reilly L A, Silke J, Metcalf D, Ekert P G, Huang D C, Cecconi F, Kuida K, Tomaselli K J, Roy S, Nicholson D W, Vaux D L, Bouillet P, Adams J M and Strasser A. (2002). Nature, 419, 634-637.

5   Murphy M, Ahn J, Walker K K, Hoffman W H, Evans R M, Levine A J and George D L. (1999). Genes Dev., 13, 2490-2501.

Nakamura S, Roth J A and Mukhopadhyay T. (2000). Mol. Cell. Biol., 20, 3224-3233.

Pluquet O and Hainaut P. (2001). Cancer Lett., 174, 1-15.

10 Rosenberg M I and Parkhurst S M. (2002). Cell, 109, 447-458.

Rubbi C P and Milner J. (2003). EMBO J., 22, 975-986.

Scaffidi C, Fulda S, Srinvasan A, Friesen C, Li F, Tomaselli K J, Debatin K-M, Kramer P H and Peter M E. (1998). EMBO J., 17, 1675-1687.

15 Shieh S-Y, Ikeda M, Taya C and Prives C. (1997). Cell, 91, 325-334.

Takata T and Ishikawa F. (2002). Biochem. Biophys. Res. Commun., 301, 250-257.

Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, 20 Lozano G, Oren M and Haupt Y. (1999). EMBO J., 18, 1805-1814.

Vaziri H, Dessain S K, Ng Eaton E, Imai S, Frye R, Pandita T K, Guarente L and Weinberg R A. (2001). Cell, 107, 149-159.

Yu J, Zhenghe W, Kinzler K W, Vogelstein B and Zhang L. (2003). Proc. Natl. Acad. Sci. USA, 100, 1931-1936.

25 Zhang L, Yu J, Ho Park B, Kinzler K W and Vogelstein B. (2000). Science, 290, 989-992.

CLAIMS

1.   A method of treating a proliferative disease comprising administering to an individual in need thereof an effective amount of a SIRT1 inhibitor.

2.   A method according to claim 1 wherein the disease is cancer.

3.   A method according to claim 2 wherein the cancer is a colorectal carcinoma.

4.   An in vitro method of inducing apoptosis in a cell comprising administering a SIRT1 inhibitor to said cell.

5.   A method according to claim 4, wherein the cell lacks at least one of functional p53, Bax and PUMA protein.

6.   A method according to claim 4 or claim 5 wherein the cell is a tumour cell.

7.   A method according to any one of claims 1 to 6, wherein the SIRT1 inhibitor is a siRNA, a dsRNA, a nucleic acid encoding such RNA, or a SIRT1 antisense RNA.

8.   A SIRT1 inhibitor for use in a method of medical treatment.

9.   A SIRT1 inhibitor for use according to claim 8, wherein said treatment is treatment of a proliferative disease.

10. A SIRT1 inhibitor for use according to claim 8 or claim 9 which is a siRNA, a dsRNA, a nucleic acid encoding such RNA or a SIRT1 antisense RNA.

11. Use of a SIRT1 inhibitor in the manufacture of a medicament for the treatment of a proliferative disease.

12. Use according to claim 11, wherein the proliferative disease is cancer.

13. Use according to claim 12, wherein the cancer is a colorectal carcinoma.

14. Use according to claim 12, wherein the cancer cells lack at least one of functional p53, Bax and protein.

15. Use according to any one of claims 11 to 14, wherein the SIRT1 inhibitor is a siRNA, a dsRNA, a nucleic acid encoding such RNA or a SIRT1 antisense RNA.

16. A siRNA which inhibits expression of SIRT1 in a cell.

17. A siRNA according to claim 16 which comprises a contiguous sequence of 10-30bp from the sequence of SEQ ID No. 2.

18. A siRNA according to claim 17 which is between 19 and 22 bp in length.

19. A siRNA according to claim 18 which is 19bp in length.

20. A siRNA according to claim 19 which has the siRNA sequence of SEQ ID No 1.

21. A composition comprising a siRNA according to any one of claims 16 to 20 and a pharmaceutically acceptable excipient.

22. The method of any one of claims 1 to 6, wherein the SIRT1 inhibitor is a siRNA according to any one of claims 16 to 20.

23. The use of any one of claims 11 to 14, wherein the SIRT1 inhibitor is a siRNA according to any one of claims 16 to 20.

24. A method of identifying a SIRT1 inhibitor for use in a method according to any one of claims 1 to 7, the method comprising
- administering a candidate compound to cultured tumour cells in vitro;
- determing whether SIRT expression and/or activity is reduced in said cells; and
- assaying for apoptosis of said cells.

25. A method according to claim 24, wherein the cells lack at least one of functional p53, Bax and protein.

26. A method according to claim 24 or claim 25, further comprising the steps of administering said candidate compound to cultured normal cells in vitro and assaying for apoptosis of said cells.

Figure 1

SIRT1
5' acuuugcuguaacccuguatt 3'
3' ttgaaacgacauugggacau 5'

Lamin A/C
5' cuggacuuccagaagaacatt 3'
3' ttgaccugaaggucuucuugu 5'

BCR-ABL
5' agaguucaaaagcccuucatt 3'
3' ttcucaaguuuucgggaagu 5'

Figure 2

A

1/27

Figure 2

B

SIRT1 Primers

CTRL SIRT1 LaminA/C BCR-ABL

+/+

CTRL SIRT1 LaminA/C BCR-ABL

-/-

C

Vimentin Primers

+/+

CTRL SIRT1 LaminA/C BCR-ABL

-/-

CTRL SIRT1 LaminA/C BCR-ABL

D

LaminA/C Primers

+/+

CTRL SIRT1 CTRL LaminA/C

-/-

CTRL SIRT1 LaminA/C BCR-ABL

Figure 3

Figure 4

A

B

Figure 4

C

Figure 5

Figure 5

B

CTRL			SIRT1			
WCE	SOL	PEL	WCE	SOL	PEL	hp53

LaminA/C			BCR-ABL			
WCE	SOL	PEL	WCE	SOL	PEL	hp53

C

WCE					
CTRL	SIRT1	CTRL	LaminA/C	CTRL	BCR-ABL

Figure 6

Figure 7

A

+/+ PEL   -/- PEL

CTRL | SIRT1 | LaminA/C | BCR-ABL | CTRL | SIRT1 | LaminA/C | BCR-ABL

B

WCE   PEL

CTRL | SIRT1 | CTRL | SIRT1

37°C + cold shock   37°C

CTRL | SIRT1 | LaminA/C | BCR-ABL | CTRL | SIRT1 | LaminA/C | BCR-ABL

Figure 7

C

D

Figure 8A

Bcr-Abl

CTRL

24

48

Figure 8A

SIRT1

LaminA/C

24

48

Figure 8B

48 hours

36 hours

24 hours

12 hours

Mock

SIRT1 siRNA

Figure 9

Bcr-Abl   CTRL

24

48

72

Figure 9

SIRT1   LaminA/C

24

48

72

Figure 10

Figure 11

1 - Mock
2 - SIRT1 siRNA
3 - Mock
4 - LaminA/C siRNA
5 - Mock
6 - BCR-ABL siRNA

Figure 12

Figure 13

NDF: Control [Mock] Transfection

72 hours

120 hours

48 hours

96 hours

Figure 13

NDF: SIRT1 siRNA Transfection

72 hours

120 hours

48 hours

96 hours

Figure 14 (1)

```
  1  ATGGCGGACG AGGCGGCCCT CGCCCTTCAG CCCGGCGGCT CCCCCTCGGC
     TACCGCCTGC TCCGCCGGGA GCGGGAAGTC GGGCCGCCGA GGGGGAGCCG

 51  GGCGGGGGCC GACAGGGAGG CCGCGTCGTC CCCCGCCGGG GAGCCGCTCC
     CCGCCCCCGG CTGTCCCTCC GGCGCAGCAG GGGGCGGCCC CTCGGCGAGG

101  GCAAGAGGCC GCGGAGAGAT GGTCCCGGCC TCGAGCGGAG CCCGGGCGAG
     CGTTCTCCGG CGCCTCTCTA CCAGGGCCGG AGCTCGCCTC GGGCCCGCTC

151  CCCGGTGGGG CGGCCCCAGA GCGTGAGGTG CCGGCGGCGG CCAGGGGCTG
     GGGCCACCCC GCCGGGGTCT CGCACTCCAC GGCCGCCGCC GGTCCCCGAC

201  CCCGGGTGCG GCGGCGGCGG CGCTGTGGCG GGAGGCGGAG GCAGAGGCGG
     GGGCCCACGC CGCCGCCGCC GCGACACCGC CCTCCGCCTC CGTCTCCGCC

251  CGGCGGCAGG CGGGGAGCAA GAGGCCCAGG CGACTGCGGC GGCTGGGGAA
     GCCGCCGTCC GCCCCTCGTT CTCCGGGTCC GCTGACGCCG CCGACCCCTT

301  GGAGACAATG GGCCGGGCCT GCAGGGCCCA TCTCGGGAGC CACCGCTGGC
     CCTCTGTTAC CCGGCCCGGA CGTCCCGGGT AGAGCCCTCG GTGGCGACCG

351  CGACAACTTG TACGACGAAG ACGACGACGA CGAGGGCGAG GAGGAGGAAG
     GCTGTTGAAC ATGCTGCTTC TGCTGCTGCT GCTCCCGCTC CTCCTCCTTC

401  AGGCGGCGGC GGCGGCGATT GGGTACCGAG ATAACCTTCT GTTCGGTGAT
     TCCGCCGCCG CCGCCGCTAA CCCATGGCTC TATTGGAAGA CAAGCCACTA

451  GAAATTATCA CTAATGGTTT TCATTCCTGT GAAAGTGATG AGGAGGATAG
     CTTTAATAGT GATTACCAAA AGTAAGGACA CTTTCACTAC TCCTCCTATC

501  AGCCTCACAT GCAAGCTCTA GTGACTGGAC TCCAAGGCCA CGGATAGGTC
     TCGGAGTGTA CGTTCGAGAT CACTGACCTG AGGTTCCGGT GCCTATCCAG

551  CATATACTTT TGTTCAGCAA CATCTTATGA TTGGCACAGA TCCTCGAACA
     GTATATGAAA ACAAGTCGTT GTAGAATACT AACCGTGTCT AGGAGCTTGT

601  ATTCTTAAAG ATTTATTGCC GGAAACAATA CCTCCACCTG AGTTGGATGA
     TAAGAATTTC TAAATAACGG CCTTTGTTAT GGAGGTGGAC TCAACCTACT

651  TATGACACTG TGGCAGATTG TTATTAATAT CCTTTCAGAA CCACCAAAAA
     ATACTGTGAC ACCGTCTAAC AATAATTATA GGAAAGTCTT GGTGGTTTTT

701  GGAAAAAAAG AAAAGATATT AATACAATTG AAGATGCTGT GAAATTACTG
     CCTTTTTTTC TTTTCTATAA TTATGTTAAC TTCTACGACA CTTTAATGAC

751  CAAGAGTGCA AAAAAATTAT AGTTCTAACT GGAGCTGGGG TGTCTGTTTC
     GTTCTCACGT TTTTTTAATA TCAAGATTGA CCTCGACCCC ACAGACAAAG

801  ATGTGGAATA CCTGACTTCA GGTCAAGGGA TGGTATTTAT GCTCGCCTTG
     TACACCTTAT GGACTGAAGT CCAGTTCCCT ACCATAAATA CGAGCGGAAC
```

Figure 14 (2)

```
 851   CTGTAGACTT CCCAGATCTT CCAGATCCTC AAGCGATGTT TGATATTGAA
       GACATCTGAA GGGTCTAGAA GGTCTAGGAG TTCGCTACAA ACTATAACTT

 901   TATTTCAGAA AAGATCCAAG ACCATTCTTC AAGTTTGCAA AGGAAATATA
       ATAAAGTCTT TTCTAGGTTC TGGTAAGAAG TTCAAACGTT TCCTTTATAT

 951   TCCTGGACAA TTCCAGCCAT CTCTCTGTCA CAAATTCATA GCCTTGTCAG
       AGGACCTGTT AAGGTCGGTA GAGAGACAGT GTTTAAGTAT CGGAACAGTC

1001   ATAAGGAAGG AAAACTACTT CGCAACTATA CCCAGAACAT AGACACGCTG
       TATTCCTTCC TTTTGATGAA GCGTTGATAT GGGTCTTGTA TCTGTGCGAC

                                                    2T1PHO
                                 T CAGTGTCATG GTTCCTTTGC
1051   GAACAGGTTG CGGGAATCCA AAGGATAATT CAGTGTCATG*GTTCCTTTGC
       CTTGTCCAAC GCCCTTAGGT TTCCTATTAA GTCACAGTAC*CAAGGAAACG

1101   AACAGCATCT TGCCTGATTT GTAAATACAA AGTTGACTGT GAAGCTGTAC
       TTGTCGTAGA ACGGACTAAA CATTTATGTT TCAACTGACA CTTCGACATG

1151   GAGGAGATAT TTTTAATCAG GTAGTTCCTC GATGTCCTAG GTGCCCAGCT
       CTCCTCTATA AAAATTAGTC CATCAAGGAG CTACAGGATC CACGGGTCGA

1201   GATGAACCGC TTGCTATCAT GAAACCAGAG ATTGTGTTTT TTGGTGAAAA
       CTACTTGGCG AACGATAGTA CTTTGGTCTC TAACACAAAA AACCACTTTT

1251   TTTACCAGAA CAGTTTCATA GAGCCATGAA GTATGACAAA GATGAAGTTG
       AAATGGTCTT GTCAAAGTAT CTCGGTACTT CATACTGTTT CTACTTCAAC

1301   ACCTCCTCAT TGTTATTGGG TCTTCCCTCA AAGTAAGACC AGTAGCACTA
       TGGAGGAGTA ACAATAACCC AGAAGGGAGT TTCATTCTGG TCATCGTGAT

1351   ATTCCAAGTT CCATACCCCA TGAAGTGCCT CAGATATTAA TTAATAGAGA
       TAAGGTTCAA GGTATGGGGT ACTTCACGGA GTCTATAATT AATTATCTCT

1401   ACCTTTGCCT CATCTGCATT TTGATGTAGA GCTTCTTGGA GACTGTGATG
       TGGAAACGGA GTAGACGTAA AACTACATCT CGAAGAACCT CTGACACTAC

                                                    ~~~~
                                                    ACUU
1451   TCATAATTAA TGAATTGTGT CATAGGTTAG GTGGTGAATA TGCCAAACTT
       AGTATTAATT ACTTAACACA GTATCCAATC CACCACTTAT ACGGTTTGAA
                                                    dTdTUGAA
         rJF3
      UGCUGUAACC CUGUAdTdT
1501   TGCTGTAACC CTGTAAAGCT TTCAGAAATT ACTGAAAAAC CTCCACGAAC
       ACGACATTGG GACATTCGA AAGTCTTTAA TGACTTTTTG GAGGTGCTTG
       ACGACAUUGG GACAU
         rJF4
```

Figure 14 (3)

```
1551   ACAAAAAGAA  TTGGCTTATT  TGTCAGAGTT  GCCACCCACA  CCTCTTCATG
       TGTTTTTCTT  AACCGAATAA  ACAGTCTCAA  CGGTGGGTGT  GGAGAAGTAC

1601   TTTCAGAAGA  CTCAAGTTCA  CCAGAAAGAA  CTTCACCACC  AGATTCTTCA
       AAAGTCTTCT  GAGTTCAAGT  GGTCTTTCTT  GAAGTGGTGG  TCTAAGAAGT

1651   GTGATTGTCA  CACTTTTAGA  CCAAGCAGCT  AAGAGTAATG  ATGATTTAGA
       CACTAACAGT  GTGAAAATCT  GGTTCGTCGA  TTCTCATTAC  TACTAAATCT

1701   TGTGTCTGAA  TCAAAAGGTT  GTATGGAAGA  AAAACCACAG  GAAGTACAAA
       ACACAGACTT  AGTTTTCCAA  CATACCTTCT  TTTTGGTGTC  CTTCATGTTT

1751   CTTCTAGGAA  TGTTGAAAGT  ATTGCTGAAC  AGATGGAAAA  TCCGGATTTG
       GAAGATCCTT  ACAACTTTCA  TAACGACTTG  TCTACCTTTT  AGGCCTAAAC

1801   AAGAATGTTG  GTTCTAGTAC  TGGGGAGAAA  AATGAAAGAA  CTTCAGTGGC
       TTCTTACAAC  CAAGATCATG  ACCCCTCTTT  TTACTTTCTT  GAAGTCACCG

1851   TGGAACAGTG  AGAAAATGCT  GGCCTAATAG  AGTGGCAAAG  GAGCAGATTA
       ACCTTGTCAC  TCTTTTACGA  CCGGATTATC  TCACCGTTTC  CTCGTCTAAT
                                        TC  TCACCGTTTC  CTCGTCTAA
                                           2T1REV

1901   GTAGGCGGCT  TGATGGTAAT  CAGTATCTGT  TTTTGCCACC  AAATCGTTAC
       CATCCGCCGA  ACTACCATTA  GTCATAGACA  AAAACGGTGG  TTTAGCAATG

1951   ATTTTCCATG  GCGCTGAGGT  ATATTCAGAC  TCTGAAGATG  ACGTCTTATC
       TAAAAGGTAC  CGCGACTCCA  TATAAGTCTG  AGACTTCTAC  TGCAGAATAG

2001   CTCTAGTTCT  TGTGGCAGTA  ACAGTGATAG  TGGGACATGC  CAGAGTCCAA
       GAGATCAAGA  ACACCGTCAT  TGTCACTATC  ACCCTGTACG  GTCTCAGGTT

2051   GTTTAGAAGA  ACCCATGGAG  GATGAAAGTG  AAATTGAAGA  ATTCTACAAT
       CAAATCTTCT  TGGGTACCTC  CTACTTTCAC  TTTAACTTCT  TAAGATGTTA

2101   GGCTTAGAAG  ATGAGCCTGA  TGTTCCAGAG  AGAGCTGGAG  GAGCTGGATT
       CCGAATCTTC  TACTCGGACT  ACAAGGTCTC  TCTCGACCTC  CTCGACCTAA

2151   TGGGACTGAT  GGAGATGATC  AAGAGGCAAT  TAATGAAGCT  ATATCTGTGA
       ACCCTGACTA  CCTCTACTAG  TTCTCCGTTA  ATTACTTCGA  TATAGACACT

2201   AACAGGAAGT  AACAGACATG  AACTATCCAT  CAAACAAATC  A
       TTGTCCTTCA  TTGTCTGTAC  TTGATAGGTA  GTTTGTTTAG  T
```

Figure 15

<pre>
hSIRT2   --
hSIRT3   --
hSIRT1   MADEAALALQPGGSPSAAGADREAASSPAGEPLRKRPRRDGPGLERSPGEPGGAAPEREV 60

hSIRT2   --
hSIRT3   -MAFWGWRAAAALRLWGRVVERVEAGGGVGPFQACGCR---------------------- 37
hSIRT1   PAAARGCPGAAAAALWREAEAEAAAAGGEQEAQATAAAGEGDNGPGLQGPSREPPLADNL 120

hSIRT2   ---MAEP-DPSHPLETQAG- 15
hSIRT3   ------------------------LVLGGRDDVSAGLRGSHGARGEPLDPARPLQRPPRP 73
hSIRT1   YDEDDDDEGEEEEAAAAAIGYRDNLLFGDEIITNGFHSCESDEEDRASHASSSDWTPRP 180
                                                 : : .: .:

hSIRT2   --------KVQEAQDSDSDSEG------GAAGGEADMDFLRNLFSQTLSLGSQKERLLDE 61
hSIRT3   --------EVPRAFRRQPRAAAPSEFFSSIKGGRRSISFSVGASSVVGSGGSSDK---GK 122
hSIRT1   RIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDI 240
                  :   :. :   .   *   .. :

hSIRT2   LTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYD--NLEKYHLPYPEAIF 119
hSIRT3   LSLQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYS--NLQQYDLPYPEAIF 180
hSIRT1   NTIEDAVKLLQ--ECKKIIVLTGAGVSVSCGIPDFRS-RDGIYARLAVDFPDLPDPQAMF 297
          ::..... ::   *:::: :.***:*...******   *:*   :: .** *:*:*

hSIRT2   EISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLE 179
hSIRT3   ELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIP 240
hSIRT1   DIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQ 357
          :: :* :.*.*** :***:***:::*..: * *: * ...:* *** ****** **:::*:

hSIRT2   QEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQS-----LVKPDIVF 234
hSIRT3   ASKLVEAHGTFASATCT--VCQRPFPGEDIRADVMADRVPRCPVCTG-----VVKPDIVF 293
hSIRT1   R--IIQCHGSFATASCL--ICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVF 413
            :::.**:* :: *   *:   . :: .:: : .*:* . .   ::**:***

hSIRT2   FGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKE------ 288
hSIRT3   FGEPLPQRFLLHVV-DFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRD------ 346
hSIRT1   FGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLH 473
          *** ** :*   :   .***:::*:**:*.*.* : .   ..*::***::

hSIRT2   ------------------KAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQG--- 327
hSIRT3   ------------------LVGP----------LAWHPR--SRDVAQLGDVVHG--- 369
hSIRT1   FDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLH 533
                            *   :   ..   :::* *.:

hSIRT2   -----------------CLALAELLGWKKELEDLVRREHASIDAQSGAGVPNPSTSASP 369
hSIRT3   -----------------VESLVELLGWTEEMRDLVQRETGKLDG--------------P 397
hSIRT1   VSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAE 593
                          :* : . .:: *: . :   :

hSIRT2   KKSPPPAKDEARTTEREKPQ-- 389
hSIRT3   DK-- 399
hSIRT1   QMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFH 653

hSIRT1   GAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAG 713

hSIRT1   GAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS 747
</pre>

Figure 16

```
SIRT1   1426   ----------   ---GTA----   ----------   ----------   ----------
SIRT2    981   ctgcct----   ----------   ----------   ----------   ----------
SIRT3   1107   cgtggaaagc   ctaGTG----   ----------   ----------   ----------
SIRT4    817.  ----------   ----------   ----------   ----------   ----------
SIRT5    821   --TTAACACG   GAGACCACCC   CAGctacgaa   cagattcagg   tttcatttcc
SIRT6    934   ----------   ----------   ----------   ----------   ----------
SIRT7   1125   gcTTAGCTCG   GCCCCCATCC   TAGggg----   ----------   ----------

               * * * * * * *   * * * * * * * * * *   * * *


SIRT1   1429   ----------   ----------   ------GAGC   TTCTTGGAga   ctgtgatgtc
SIRT2    987   ----------   ------GGCC   CTTGCTGAGC   TCCTTGGATG   GA--------
SIRT3   1123   ----------   ----------   ------GAGC   TTCTGGGCTG   GA--------
SIRT4    817   ----------   ----------   ---------C   TCACTGCCTG   GG--------
SIRT5    869   agggaccctg   tggaacGACT   CTTCCTGAAG   CCCTTGCCTG   tc--------
SIRT6    934   ----------   ----------   ---------C   CCGCCGGCCC   CA--------
SIRT7   1151   ----------   ----------   ----------   ----------   ----------

               * * * *   * * * * * * * * * *   .* * * * * * * * * *   * *


SIRT1   1453   ataattaatg   aattgtgtca   taggttaggt   ggtgaatatg   ccaaactttg
SIRT2   1013   ----------   ----------   ----------   ----------   ----------
SIRT3   1139   ----------   ----------   ----------   ----------   ----------
SIRT4    830   ----------   ----------   ----------   ----------   ----------
SIRT5    911   ----------   ----------   ----------   ----------   ----------
SIRT6    947   ----------   ----------   ----------   ----------   ----------
SIRT7   1151   ----------   ----------   ----------   ----------   ----------


SIRT1   1503   ctgtaaccct   gtaaagcttt   cagaaattac   tgaaaaacct   ccacgaacac
SIRT2   1013   ----------   ----------   ----------   ----------   ----------
SIRT3   1139   ----------   ----------   ----------   ----------   ----------
SIRT4    830   ----------   ----------   ----------   ----------   ----------
SIRT5    911   ----------   ----------   ----------   ----------   ----------
SIRT6    947   ----------   ----------   ----------   ----------   ----------
SIRT7   1151   ----------   ----------   ----------   ----------   ----------


SIRT1   1553   aaaaagaatt   ggcttatttg   tcagagttgc   cacccacacc   tcttcatgtt
SIRT2   1013   ----------   ----------   ----------   ----------   ----------
SIRT3   1139   ----------   ----------   ----------   ----------   ----------
SIRT4    830   ----------   ----------   ----------   ----------   ----------
SIRT5    911   ----------   ----------   ----------   ----------   ----------
SIRT6    947   ----------   ----------   ----------   ----------   ----------
SIRT7   1151   ----------   ----------   ----------   ----------   ----------
```

Figure 17 (1)

```
hSIRT2   ------------------------------------------------------------
hSIRT3   -----------------MAFWGWRAAAALRLWGRVVERVEAGGGVGPFQACGCRLVLGGRDDV 46
hSIRT1   MADEAALALQPGGGSPSAAGADREAASSPAGEPLRKRPRRDGPGLERSPGEPGGAAPEREV 60
hSIRT4   ------------------------------------------------------------
hSIRT7   ------------------------------------------------------------
hSIRT6   ----------------------------MAAGGLSRSERKAAERVRRLREEQQ 25
hSIRT5   ------------------------------------------------------------


hSIRT2   ----------MAEP-DPSHPLETQAG-KVQEAQDSDSDSEG------GAAGGEADMDFLR 42
hSIRT3   SAGLRGSHGARGEPLDPARPLQRPPRPEVPRAFRRQPRAAAPSFFFSSIKGGRRSISFSV 106
hSIRT1   PAAARGCPGAAAAALWREAEAEAAAAGGEQEAQATAAAGEGDN--GPGLQGPSREPPLAD 118
hSIRT4   --------------MKMSFALTFRSAKGRWIANPSQP-------------CSKASIGLFV 33
hSIRT7   RERLR-----QVSRILRKAAAERSAEEGRLLAESADLVTELQG-------RSRRREGLKR 73
hSIRT6   ------------------MSVNYAAGLSPYADK----------------GKCGLPEIFD 25
hSIRT5   ----------------MRPLQIVPSRLISQLYCGLKPP------------ASTRNQICLK 32


hSIRT2   NLFSQTLSLGSQKER--------------------------------------------- 57
hSIRT3   GASSVVGSGGSSDK---------------------------------------------- 120
hSIRT1   NLYDEDDDDEGEEEEEAAAAAIGYRDNLLFGDEIITNGFHSCESDEEDRASHASSSDWTP 178
hSIRT4   PASPP------------------------------------------------------- 38
hSIRT7   RQEEVCD---------------------------------------------------- 80
hSIRT6   PPEE------------------------------------------------------- 29
hSIRT5   MARP------------------------------------------------------- 36


hSIRT2   ---------------------------------LLDELTLEGVARYMQSE--------- 74
hSIRT3   --------------------------------GKLSLQDVAELIRAR--------- 135
hSIRT1   RPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRK 238
hSIRT4   --------------------------------LDPEKVKELQRFITLS--------- 54
hSIRT7   --------------------------------DPEELRGKVRELASAVR------ 97
hSIRT6   --------------------------------LERKVWELARLVWQS--------- 44
hSIRT5   --------------------------------SSSMADFRKFFAKA--------- 50


hSIRT2   ---------------RCRRVICLVGAGISTSAGIPDFRSPSTGLYD--NLEKYHLPYPEAIF 119
hSIRT3   -------------ACQRVVVMVGAGISTPSGIPDFRSPGSGLYS--NLQQYDLPYPEAIF 180
hSIRT1   DINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRS-RDGIYARLAVDFPDLPDPQAMF 297
hSIRT4   --------------KRLLVMTGAGISTESGIPDYRSEKVGLYAR--TDRRPIQHGDFVR 97
hSIRT7   -------------NAKYLVVYTGAGISTAASIPDYRG-PNGVWT-----LLQKGRSVS 136
hSIRT6   ---------------SSVVFHTGAGISTASGIPDFRG-PHGVWT--------MEERGLAP 80
hSIRT5   --------------KHIVIISGAGVSAESGVPTFRG-AGGYWR--KWQAQDLATPLAFA 92
                     ::    ***:*. ..:* :*.    * :            :


hSIRT2   EISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLE 179
hSIRT3   ELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIP 240
hSIRT1   DIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQ 357
hSIRT4   SAPIRQRYWARNFVGWPQFSS--HQPNPAHWALSTWEKLGKLYWLVTQNVDALHTKAGSR 155
hSIRT7   AADLS---------------EAEPTLTHMSITRLHEQKLVQHVVSQNCDGLHLRSGLP 179
hSIRT6   KFDTTFES-------------ARPTQTHMALVQLERVGLLRFLVSQNVDGLHVRSGFP 125
hSIRT5   HNPSRVWEFYHYRREVMGSKEPNAGHRAIAECETRLGKQGRRVVVITQNIDELHRKAGTK 152
                                           :** * *.   :*
```

26/27

Figure 17 (2)

```
hSIRT2      QEDLVEAHGTFYTSHCVSASCRHEYPLSW-MKEKIFSEVTPKCEDCQS--------LVKP 230
hSIRT3      ASKLVEAHGTFASATCT--VCQRPFPGED-IRADVMADRVPRCPVCTG--------VVKP 289
hSIRT1      R--IIQCHGSFATASCL--ICKYKVDCEA-VRGDIFNQVVPRCPRCPADEP---LAIMKP 409
hSIRT4      R--LTELHGCMDRVLCLD--CGEQTPRGV-LQERFQVLNPTWSAEAHG--------LAPD 202
hSIRT7      RTAISELHGNMYIEVCTSCVPNREYVRVFDVTERTALHRHQTGRTCHKCG-----TQLRD 234
hSIRT6      RDKLAELHGNMFVEECAK--CKTQYVRDTVVGTMGLKATGRLCTVAKARGLRACRGELRD 183
hSIRT5      N--LLEIHGSLFKTRCTS-----------CGVVAENYKSPICPALSG--------KGAP 190
                :  :  **  :        *

hSIRT2      DIVFFGES-LPARFFS--CMQSDFLKVDLLLVMGTSLQVQ---PFASLISKAPLSTPRLL 284
hSIRT3      DIVFFGEP-LPQRFLL--HVV-DFPMADLLLILGTSLEVE---PFASLTEAVRSSVPRLL 342
hSIRT1      EIVFFGEN-LPEQFHR--AMKYDKDEVDLLIVIGSSLKVR---PVALIPSSIPHEVPQIL 463
hSIRT4      GDVFLSEE-QVRSFQVPTCVQCGGHLKPDVVFFGDTVNPD---KVDFVHKRVKEADSLLV 258
hSIRT7      TIVHFGERGTLGQPLNWEAATEAASRADTILCLGSSLKVLKKYPRLWCMTKPPSRRPKLY 294
hSIRT6      TILDWEDS-LPDRDLA--LADEASRNADLSITLGTSLQIR---PSGNLPLATKRRGGRLV 237
hSIRT5      EPGTQDASIPVEKLPRCEEAGCGGLLRPHVVWFGENLDPA---ILEEVDRELAHCDLCLV 247
                             :  :*  .:.                          :

hSIRT2      INKE----------------------KAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAW 320
hSIRT3      INRD----------------------LVGP------------LAWHPR--SRDVAQ 362
hSIRT1      INREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAY 523
hSIRT4      VGSS-------------------------LQVYSGYRFILTAWEKKLPIAILN 286
hSIRT7      IVNLQWTP--------------------KDDWAALKLHGKCDDVMRLLMAELGLEIPA 332
hSIRT6      IVNLQP----------------------TKHDRHADLRIHGYVDEVMTRLMEHLGLEIPA 275
hSIRT5      VGTS-------------------------------SVVYPAAMFAPQVAARGVPVAE 273
            :                                            :              :

hSIRT2      LGECDQG-------------------CLALAELLGWKKELEDLVRREHASIDAQSGAG 359
hSIRT3      LGDVVHG-------------------VESLVELLGWTEEMRDLVQRETGKLDG----- 396
hSIRT1      LSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQ 583
hSIRT4      IGPTRSD-------------------DLACLKLNSRCGELLPLIDPC---------- 314
hSIRT7      YSRWQDP-------------------IFSLATPLRAGEEGSHSRKSLCRSREEAPPG 370
hSIRT6      WDGPRVLER-------------ALPPLPRPPTPKLEPKEESPTRINGSIPAGPKQEPCA 321
hSIRT5      FNTETTP-------------------ATNRFRFHFQGPCGTTLPEALACHENETVS- 310

hSIRT2      VPNPSTSASPKKSPPPAKDEARTTEREKPQ-------------------------------- 389
hSIRT3      ---------PDK-------------------------------------------------- 399
hSIRT1      TSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYL 643
hSIRT4      ------------------------------------------------------------
hSIRT7      DRGAPLSSAPILGGWFGRGCTKRTKRKKVT------------------------------ 400
hSIRT6      QHNGSEPASPKRERPTSPAPHRPPKRVKAKAVPS-------------------------- 355
hSIRT5      ------------------------------------------------------------

hSIRT1      FLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLE 703


hSIRT1      DEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS 747
```